[go: up one dir, main page]

WO1994005300B1 - Utilisation de la rapamycine dans le traitement du sida - Google Patents

Utilisation de la rapamycine dans le traitement du sida

Info

Publication number
WO1994005300B1
WO1994005300B1 PCT/CA1993/000384 CA9300384W WO9405300B1 WO 1994005300 B1 WO1994005300 B1 WO 1994005300B1 CA 9300384 W CA9300384 W CA 9300384W WO 9405300 B1 WO9405300 B1 WO 9405300B1
Authority
WO
WIPO (PCT)
Prior art keywords
rapamycin
medicament
mammal
body weight
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1993/000384
Other languages
English (en)
Other versions
WO1994005300A1 (fr
Filing date
Publication date
Application filed filed Critical
Priority to AU48123/93A priority Critical patent/AU4812393A/en
Publication of WO1994005300A1 publication Critical patent/WO1994005300A1/fr
Publication of WO1994005300B1 publication Critical patent/WO1994005300B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention concerne l'utilisation de la rapamycine ou d'un de ses analogues pour fabriquer un médicament destiné à traiter une infection par HIV ou à en bloquer l'évolution ou en retarder la progression, s'il est administré en quantité suffisante pour abaisser le niveau de l'antigène p24 sérique. Elle porte aussi sur l'utilisation de la rapamycine ou d'un de ses analogues pour traiter, chez un mammifère, le SIDA ou en bloquer l'évolution ou en retarder la progression. Elle porte enfin sur un procédé permettant de traiter, chez un mammifère, le SIDA ou d'en bloquer l'évolution ou d'en retarder la progression, en lui administrant une quantité de rapamycine ou d'analogue de rapamycine suffisante pour abaisser le niveau de l'antigène p24 sérique.
PCT/CA1993/000384 1992-09-03 1993-09-02 Utilisation de la rapamycine dans le traitement du sida Ceased WO1994005300A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48123/93A AU4812393A (en) 1992-09-03 1993-09-02 Use of rapamycin in the treatment of aids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93877492A 1992-09-03 1992-09-03
US938,774 1992-09-03
US10282293A 1993-08-06 1993-08-06
US102,822 1993-08-06

Publications (2)

Publication Number Publication Date
WO1994005300A1 WO1994005300A1 (fr) 1994-03-17
WO1994005300B1 true WO1994005300B1 (fr) 1994-04-14

Family

ID=26799773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1993/000384 Ceased WO1994005300A1 (fr) 1992-09-03 1993-09-02 Utilisation de la rapamycine dans le traitement du sida

Country Status (2)

Country Link
AU (1) AU4812393A (fr)
WO (1) WO1994005300A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42889E1 (en) 1992-08-25 2011-11-01 G.D. Searle Llc α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
USRE43802E1 (en) 1992-08-25 2012-11-13 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637774C (fr) 1993-09-10 2011-07-19 Emory University Nucleosides avec activite virale anti-hepatite b
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
US20060099170A1 (en) * 2002-09-13 2006-05-11 Redfield Robert R Compositions for inducing increased levels of beta-chemokines and methods of use therefor
WO2005001027A2 (fr) * 2003-05-16 2005-01-06 University Of Maryland Biotechnology Institute Compositions de regulation de l'insensibilisation de la cellule au facteur de l'expression ccr5 et leurs methodes d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093338A (en) * 1991-04-23 1992-03-03 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42889E1 (en) 1992-08-25 2011-11-01 G.D. Searle Llc α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
USRE43802E1 (en) 1992-08-25 2012-11-13 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
IE893690L (en) Treatment of obesity
HK26087A (en) Method of contraception and pharmaceutical package therefor
KR930007441A (ko) 의약품
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
AU601237B2 (en) The use of paroxetine to treat pain
RU95117097A (ru) ПРИМЕНЕНИЕ ДИДЕЗОКСИ-АНАЛОГОВ НУКЛЕОЗИДОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, СПОСОБ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, β -Z-5-ФТОР-2',3'-ДИДЕЗОКСИЦИТОЗИН И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ ПРОИЗВОДНЫЕ
KR910700045A (ko) Hiv 감염 관련 질병의 치료
JP2002528502A5 (fr)
US4425363A (en) Treatment of tardive dyskinesia in mammals
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
WO1994005300B1 (fr) Utilisation de la rapamycine dans le traitement du sida
PT1027053E (pt) Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
MY124465A (en) Reduction of infarct volume using citicoline
KR890004705A (ko) 항바이러스성 제제
EP0362162B1 (fr) Composition pharmaceutique comprenant de la zinovudine et de l'inosiplex ou leurs composants pour le traitement du SIDA ou de syndromes apparentés au SIDA
IE851848L (en) Propiophenone compound against sexual dysfunction
KR910007528A (ko) 벤조디아제핀 및 페닐피릴케톤 유도체의 용도
JPH0222227A (ja) エイズカヘキシーの酢酸メゲストロールによる処置法
WO1992007564A2 (fr) Procede de traitement des maladies demyelinisantes
KR900701301A (ko) 후천성 면역 결핍증과 연관된 골수억제증의 치료방법
US6090799A (en) Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
WO2000043014A3 (fr) MUTATIONS DE VIH-1 SELECTIONNEES A L'AIDE DE β-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE